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Abstract: 
HIF-1 α (hypoxia inducible factor-1 α isoform) has been exploited as a target in cancer therapeutics. HIF-1 α is the isoform-2 of HIF-1 α subunit. 
It is a 735 residues long protein modeled in this study. The HIF-1 α is absolutely critical for continued survival of cancer cells as it is involved in 
the activation of glycolysis and it helps an oxygen-starved cell convert sugar to energy without using oxygen. It also initiates angiogenesis to 
bring in a fresh oxygen supply. HIF-1 α operates only in presence of free radicals. In the present study, five antioxidants, namely lycopene, 
ascorbic acid, α-tocopherol, curcumin and curcumin dipiperoyl ester which are potent scavengers of reactive oxygen species (ROS) have been 
docked to HIF-1 α modeled protein in order to assess their binding and consequently, their inhibitory activity. The binding energy score has been 
found to be in the order, curumin dipiperoyl ester > lycopene > curcumin > tocopherol > ascorbic acid. However, subsequent experiments should 
be designed to validate these observations. 
 
Background:  
One of the important factors highlighted recently in cancer is the 
activation of glycolysis leading to angiogenesis [1] and cell 
proliferation, decreased apoptosis, cellular immortalization
  and 
invasion/metastasis. Novel molecules for cell proliferation are 
provided through glycolysis, which is activated by the well known 
factor HIF-1 α [2-4]. Transcription factor is a guide to many cancers 
by activating the transcription of many genes that
 code for proteins 
involved in several pathways which are closely related
  to cancer 
growth. The progressive survival of cancer cells depends on glycolytic 
energy through ATP
 generation
 [5-6] and the level of ATP is reduced 
remarkably under oxygen starved conditions in the absence of HIF-1 α 
[2]. In most common human
 cancers as well as in pre-neoplastic and 
pre-malignant lesions, such as colonic adenoma,
  breast ductal 
carcinoma HIF-1 α is over-expressed. It is reported that HIF-1 α 
expression may
 occur very early in carcinogenesis, before histological 
evidence
 of angiogenesis or invasion [3]. It has been suggested that 
HIF-1  α is a biomarker of carcinogenesis and for drug design, 
pharmaceutical companies use it as suitable target for cancer
 chemo-
prevention.  
 
Studies suggest that HIF-1 α can only operate in the presence of free 
radicals and it does not work if antioxidants remove these free radicals 
[7]. They showed that while this protein was abundant in untreated 
cancer cells taken from mice, it disappeared in vitamin C-treated cells. 
It might be possible that antioxidants adopted two alternative pathways 
for reducing the activity of HIF-1 α, firstly, these directly remove the 
free radicals and make the survival of HIF-1 α difficult and another 
way may be that these antioxidants bind at the active site of the protein 
to inhibit its activity. HIF1 is a hetero-dimer composed of two subunits 
(an alpha and a beta). The beta subunit has been recognized as the aryl 
hydrocarbon receptor nuclear trans-locator (ARNT) [9]. Two 
alternative transcripts of hypoxia inducible factor-1gene encodes for 
different isoforms (NP_001521.1 and NP_851397.1). The HIF1 alpha 
is isoform 2 (NP_851397.1) and it is shorter with a distinct C-
terminus, compared to isoform 1 as it lacks an alternate segment at the 
3' CDS region. Therefore, it is important to describe the mechanism of 
in induction by HIF-1 α. However, the protein databank (PDB) 
contains the NMR structure of cysteine/histidine-rich 1 (CH1) domain 
of p300 bound to the C-terminal transactivation domain of HIF-1α, 
which is smaller than the target receptor protein [8]. Hence, we 
employed threading technique to construct the model. We then used 
docking tools to evaluate the binding of anti-oxidants like lycopene, 
curcumin, α tocopherol and ascorbic acid. We also docked curcumin 
dipiperoyl ester for comparison as its bioavailability is enhanced 
remarkably to curcumin and it is a potent anticancer drug to curcumin 
[10].  
Methodology: 
Target sequence:  
The 735 residue long protein sequence of Human hypoxia inducible 
factor 1 (NCBI_ID: NP_851397.1 (hypoxia-inducible factor 1, alpha 
subunit isoform 2) was downloaded from NCBI RefSeq database [12].   
 
BLAST search:  
The target sequence for HIF-1 alpha was submitted to NCBI-Blast and 
searched against PDB [13] to select suitable structural templates.   
 
Wurst server:  
Wurst server is used in the absence of a suitable homolog. The target 
sequence is aligned to more than 3000 templates using a dynamic 
programming algorithm with a structure and sequence features based 
score function [14].   
 
ArchPRED:  
We used ArchPRED for loop region prediction [15]. 
 
SwissPdbViewer:  
We used swisspdbviewer to subsequently model the structure using the 
selected template and loop structures [16]. 
 
RAMPAGE server:  
The RAMPAGE server is used to validate the predicted model [17].  
 
Discussion: 
Ramachandran plot analysis of the modelled structure show 77.4%  in 
favoured region, 14.1% in allowed region and 8.1% in outlier region 
of the plot. This modeled protein structure has five cavities detected 
using the  molegro software with  volumes 288.768 A
3,  29.184 A
3, 
26.112 A
3, 25.6 A
3 and 19.968 A
3. The cavity with volume  288.768 
A
3 shows  good energy score for all the five antioxidants (lycopene, 
ascorbic acid, tocopherol, curcumin and dipiperoyl ester of curcumin) 
used in this study. The ranking of the anti-oxidants using the energy 
score is curcumin-dipiperoyl ester ‹ lycopene ‹ curcumin ‹ tocopherol ‹ 
ascorbic acid. Data shows curcumin dipiperoyl ester with the lowest 
energy score is most favourable. The five antioxidants used in the 
study exhibit hydrogen bond interaction with the interacting residues 
as shown in Figures 1. The analysis shows ascorbic acid with 
maximum H-bond interaction and tocopherol with minimum H-bond 
interactions.  Table 1 (see supplementary material) shows the 
interacting properties of the anti-oxidants to the target protein. 
Curcumin also show low energy score which is close to lycopene. The 
energy score of curcumin molecule was changed by substituting it 
with dipiperoyl ester as reported eslwehere [11].  
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Figure 1: HIF-1 α protein docked with (a) curcumin dipiperoyl ester; (b) curcumin; (c) lycopene; (d) tocopherol; (e) ascorbic acid 
 
Conclusion: 
It is known that antioxidants inhibit the activity of HIF-1 α by 
scavenging free radicals. Data here show that the five antioxidants 
(lycopene, ascorbic acid, α- tocopherol, curcumin and curcumin 
conjugates with piperic acid) have similar mode of binding at the site 
of the hypoxia inducing factor-1 α with varying binding energy scores. 
Current analysis also shows the H-bonds interactions of these 
compounds with the active sites. However, subsequent experiments 
should be designed to validate these observations. 
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Supplementary material:  
 
 Table1: Comparative binding Energy Scores of the five antioxidants 
Antioxidants  MolDock Score  
(Energy Score) 
H-bond interaction 
energy 
Common interacting residues 
 
Dipiperoyl ester of curcumin  -200.299  -3.393  Pro 482, Glu 512, Pro 513, Tyr 522, Thr 651, Thr 655  
Lycopene  -182.405  -2.5  Pro 482, Leu485, Pro513, Tyr522, Thr651, Thr655  
Curcumin  -151.557  -3.8  Leu485, Glu486, Thr651, Thr655 
Tocopherol  -128.9  0.27  Leu485, Glu486, Glu512,  Pro 513, Tyr 522 
Ascorbic acid  -94.5  -19.4  Leu485, Glu486, Glu512  
 